EUDA Health vs NewGenIvf
EUDA and NIVF side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How EUDA and NIVF compare
NewGenIvf grew revenue faster over the last twelve months (336% versus 70.0% for EUDA Health).
NewGenIvf keeps more of each dollar of sales as profit, with a net margin of 41.7% compared with −40.7% at EUDA Health.
NewGenIvf scores higher on the StockData Score (7 against 5 for EUDA Health), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | EUDA | NIVF |
|---|---|---|
| Size and price | ||
| Share price | $15.55 | $0.231 |
| Change, 1 year | −73.6% | −100.0% |
| Beta (5Y) | 0.34 | 2.87 |
| Employees | 123 | 87 |
| StockData Score | ||
| Total score | 5 | 7 (better) |
| Valuation score | 0 | 0 |
| Growth score | 3 (better) | 2 |
| Performance score | 1 | 4 (better) |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | 70.0% | 336% (better) |
| Profitability | ||
| Gross margin | 43.9% (better) | 4.0% |
| Operating margin | −36.3% (better) | −45.2% |
| Net margin | −40.7% | 41.7% (better) |
| FCF margin | −36.7% (better) | −46.7% |
| Return on equity | −245% | 77.9% (better) |
| Return on invested capital | −227% | −70.9% (better) |
| Financial health | ||
| Interest coverage | −10.8× (better) | −17.4× |
| Current ratio | 2.53 (better) | 1.06 |
| Piotroski F-score | 5 | 5 |
| Ownership | ||
| Held by insiders | 24.4% | – |
| Insider net buying, 12 months | – | $4.2M |
Go deeper
- EUDA stock overview
- EUDA income statement
- EUDA valuation and score
- NIVF stock overview
- NIVF income statement
- NIVF valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.